Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...
Hosted on MSN1mon
Tectonic shares tumble after rival drug trial terminationThe market's reaction reflects concerns over the future of TECX's lead product candidate, TX45, which targets the same RXFP1 receptor as Lilly's volenrelaxin. The termination of Lilly's ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback